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Objectives: to investigate the variables affecting the long-term outcome of infrainguinal vein bypass grafts that have
undergone postoperative surveillance.
Design: a retrospective analysis.
Patients and methods: details of 299 consecutive infrainguinal vein grafts performed in 275 patients from a single
university hospital were collected and analysed. All grafts underwent postoperative duplex surveillance. Factors affecting
patency, limb salvage and survival rates were examined. These factors were gender, diabetes, hypertension, aspirin,
warfarin, ischaemic heart disease, run-off, graft type, early thrombectomy, level of anastomoses and indication for surgery.
Results: the 6-year primary, primary assisted and secondary patency rates were 23, 47, and 57%, respectively. Six-year
limb salvage and patient survival were 68 and 45%, respectively. Primary patency was adversely influenced by the use
of composite vein grafts. Early thrombectomy was the only factor that significantly influenced secondary patency. Limb
salvage was worse in diabetic limbs, limbs with poor run-off and in grafts that required early thrombectomy. Postoperative
survival was better in males, claudicants and in patients who took aspirin.
Conclusions: although co-morbid factors did not influence graft patency rates, diabetes did adversely effect limb salvage.
This study, like others before it, confirms that aspirin significantly reduces long-term mortality in patients undergoing
infrainguinal revascularisation.
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Introduction Patients and Methods
Infrainguinal bypass surgery has entered a new era. Between 1988 and 1994 our vascular unit, set in a
Modern practice recognises the benefits of autologous university teaching hospital performed 299 con-
vein,1–3 meticulous surgical technique and post- secutive infrainguinal vein graft reconstructions in 275
operative duplex surveillance.4–7 Outcome is usually patient. It was the policy of the unit at that time to
expressed in terms of graft patency, limb salvage and use prosthetic grafts for above-knee popliteal bypasses.
patient survival. The effect of clinical risk factors on Hence 275 (92%) grafts were infrageniculate, whilst
these outcomes is controversial. For example, there only 24 (8%) grafts were suprageniculate. The in-
is no consensus on the influence of smoking8–11 or dication for surgery was critical limb ischaemia (CLI)
diabetes12,13 on graft patency rates and recent studies in 258 (87%) cases and claudication in 40 (13%) patients.
suggest that gender may play a more significant role All the patients who had CLI fulfilled the European
than previously thought.14,15 However, relatively few8,9 Consensus Document Criteria.16 All patients under-
of these studies have been performed on grafts that went detailed preoperative angiography. The vein of
have been subject to long-term postoperative duplex first choice was the long saphenous and this was
surveillance. The aim of this study therefore was to assessed and marked preoperatively using a duplex
examine the association between clinical variables and scanner (Diasonics sonstron, Bedford, U.K.). If the vein
long-term outcome in a consecutive series of infra- was inadequate as a result of length, calibre (<3 mm),
inguinal vein grafts that had undergone postoperative previous surgery, or varicosities, then arm veins were
graft surveillance. marked for use. Thus a composite graft would consist
of suitable segments of autogenous vein that have* Please address all correspondence to: N. J. M. London, Department
of Surgery, University of Leicester, Leicester LE2 7LX. been sutured together to form a conduit of adequate
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length. Both the in situ and reversed techniques were been restored with flow in most of the original graft
and at least one anastomoses by an additional pro-used. To confirm the suitability of the vessel on to
which to perform the distal anastomosis, an intra- cedure.18 Limb salvage refers to the avoidance of major
amputation in patients with CLI. The Mantel–Haenszeloperative prereconstruction angiogram was per-
formed and at the conclusion of the procedure a log-rank test19 was used to perform a univariate ana-
lysis of the effect of the factors outlined above oncompletion arteriogram was performed. Post-
operatively all the vein grafts underwent long-term outcome. Primary patency was analysed because it
examines the influence of variables on pathologicalduplex graft surveillance which commenced at the
first postoperative month and continued at 3-monthly events (such as perioperative hypercoaguability or
intimal hyperplasia) that may lead to graft failure.intervals for the first year and 6-monthly thereafter.
At each examination, the entire graft was insonated Secondary patency was analysed because it examined
the impact of factors affecting the patency of the graftand the peak velocity ratio across a suspected stenoses
was calculated. A peak velocity ratio of [3.0 was after interventional procedures. The factors influencing
limb salvage and patient survival were also analysed.defined as a significant stenoses. Such lesions were
corrected by percutaneous transluminal angioplasty Factors that had a significant effect on univariate ana-
lysis (p<0.05) were entered into a Cox multivariatein the majority of cases.
The clinical variables examined were gender, pres- model20 in order to identify those variables that in-
dependently influenced outcome. There was no dif-ence of diabetes, hypertension, ischaemic heart disease,
presence of critical ischaemia, level of distal ana- ference in results when either forward stepwise entry
or a backward stepwise elimination methods werestomosis, number of run-off vessels, use of post-
operative warfarin and or anti-platelet therapy, used in the Cox multivariate model. The analysis took
account of any missing data.technique of vein grafting and early postoperative
(within 30 days) graft thrombosis. Although the effect
of smoking on the outcome of lower-limb re-
vascularisation is an important issue, it is controversial,
Resultsparticularly if no objective test of smoking (e.g. urinary
cotinine) is used. We had to rely on patient history, and
Of the 299 vein grafts, 159 (53%) were in situ, 115because this is incorrect in about 25% of patients,10 we
(38%) were reversed and 25 (8%) were arm/saphenousdid not examine this variable. If the patient was not
vein composite grafts. The median (range) age of thetaking warfarin, it was prescribed for patients whose
patients was 71 years (19–97). In male patients thegrafts had required thrombectomy. Patients were pre-
median (range) age was 70 (19–97), in females it wasscribed aspirin as prophylaxis against cerebro- or
75 (37–94). This difference was statistically significantcardiovascular thrombosis. The status of the distal run-
(p=0.001 Mann–Whitney u-test). The overall medianoff vessels was recorded as the number of patent vessels
(range) follow up was 19 months (1–102). The min-determined by the intraoperative assessment outlined
imum period of follow-up of patients that were aliveabove. Graft patency was determined by duplex sur-
with patent grafts was 19 months. The 30-day operativeveillance.
mortality was 7.7%; 6.4% in males, 10.9% in females.
Fifty-five (18%) grafts occluded within the first 30
postoperative days, of which 20 occurred within 24 h.
The 6-year primary, primary assisted and secondaryData analysis
patency rates for all the grafts was 23, 47 and 57%,
respectively (Fig. 1). The 6-year cumulative patientA database was created using SPSS (Microsoft, U.S.A.).
Twenty-one patients were lost to follow-up, and their survival and limb salvage was 45 and 68%, respectively
(Fig. 2). The prevalence of the clinical variables ana-details were censored to the last surveillance visit.
The 6-year primary, primary assisted and secondary lysed is listed in Table 1.
The results of univariate analysis of the factorspatency rates of the series was determined and re-
ported by constructing a Kaplan–Meier life table17 as affecting patency, limb salvage and patient survival
rates are shown in Table 2. Primary patency wasrecommended by the ad hoc committee of the society
of vascular surgery.18 Primary patency is defined as influenced only by the use of composite vein grafts,
which adversely affected 6-year patency. As this wasuninterrupted patency not requiring additional pro-
cedures. Primary assisted patency refers to grafts that the only significant variable, a Cox multivariate ana-
lysis was not performed. Secondary patency on uni-have had a procedure performed in order to prevent
thrombosis. Secondary patency is when patency has variate analysis was significantly impaired by the
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Fig. 1. Cumulative primary E, primary assisted F, and secondary patency A of all vein grafts. There was a significant difference
between all patency rates, overall p value, 0.0001 (log rank test) S.E. at all time points was less than 10%
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Fig. 2. Cumulative patient survival F and cumulative limb salvage E for patients with critical limb ischaemia (CLI) S.E. at all time
points <10%.
presence of critical ischaemia, the use of composite Conversely, secondary patency was significantly im-
proved in patients taking aspirin. When these factorsvein, postoperative warfarin and by grafts that had
required thrombectomy within 30 days of surgery. were analysed in the multivariate model, postoperative
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Table 1. Prevalence of factors in 299 vein grafts. (gender M/F, odds ratio 1.7, p<0.02; aspirin, odds ratio
1.8, p<0.001; CLI, odds ratio 0.3, p<0.006).Factor Number (%)
Gender
Males 204 (68)
Females 95 (32)
Discussion
Diabetes
Yes 91 (31)
No 207 (69) Although the outcome of lower-limb revascularisation
1 NR has improved with the use of autologous vein, me-
Hypertension ticulous surgical technique and postoperative graft sur-
Yes 112 (38) veillance,1–7 the question remains whether clinicalNo 185 (62)
factors can be modulated in order to improve outcome2 NR
even further. Our analysis showed that only the use ofIschaemic heart disease
Yes 76 (26) composite vein made a significant difference to primary
No 220 (74) patency. Other large studies21,22 have reported a similar
Aspirin adverse impact of composite vein on primary patency.
Yes 141 (54) Composite vein is only used when there is inadequateNo 122 (46)
good quality long saphenous vein and it is not therefore36 NR
surprising that the patency of composite vein is in-Warfarin
Yes 170 (64) ferior.21,23–25 When Donaldson and colleagues analysed
No 94 (36) primary graft failure in 455 in situ grafts, they found
35 NR
that a variety of technical and patient specific reasons
Type of graft accounted for the early failures in their series.22 TheyIn situ 159 (53)
suggested that a more conservative patient selectionReversed 115 (38)
Composite 25 (8) may have improved their results. However, the benefits
Indication of an aggressive and non-selective approach to lower-
CLI 258 (87) limb revascularisation has been demonstrated in our
Claudication 40 (13)
unit9 as well as by others28,29 and this policy may have1 NR
contributed to the relatively high early failure rate seenRun-off vessels
in this study.One or less 158 (53)
Two or more 141 (47) There is a marked difference between the primary
Distal anastomoses and primary assisted patency rates in this study, 23
Popliteal artery 104 (35) and 47%, respectively. The 6-year primary patency
Tibial and distal arteries 193 (65)
rate in the present study is less than the 5-year patency2 NR
reported from this unit prior to graft surveillanceGraft thrombectomy or additional procedures
(42%), implying that grafts would continue to fail overYes 55 (18)
No 244 (82) time.30 This suggests that the assisted graft patency
NR, status of factor not recorded rates observed in this study would be as a result of our
graft surveillance and early intervention programme.
However, this study was not designed to evaluate the
effects of our surveillance programme on patency ratesthrombectomy was the only independent factor that
affected secondary patency (odds ratio 0.2, p<0.001). and has no randomised comparative data. Therefore,
such conclusions would be speculative.Univariate analysis showed that limb salvage was
adversely influenced by the presence of diabetes, fe- The only factor that influenced long-term secondary
patency was early graft thrombectomy. This is con-male sex, poor run-off, graft thrombectomy and com-
posite vein. In the multivariate analysis, diabetes (odds sistent with reports from other modern series.26,27
Neilsen and colleagues found that vein-grafts thatratio 0.5, p<0.008), graft thrombectomy (odds ratio 0.2,
p<0.001) and poor run-off (odds ratio 0.6, p<0.047) required thrombectomy within 30 days of surgery
had a two-fold risk of developing stenosis as well asremained as independent adverse factors (Table 3).
Diabetes, female sex, and CLI adversely influenced reduced secondary patency rates.26 Prior to the advent
of postoperative surveillance, poor run-off vesselspatient survival in the univariate analysis. However,
patients on aspirin had a significantly better long-term were reported to significantly influence secondary vein
graft patency.31–35 Some of these reports were frompostoperative survival. In the multivariate analysis,
all of these factors except diabetes remained significant studies in which most of the vein grafts were inserted
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Table 2. Log rank univariate analysis of variables affecting patency, limb salvage and patient survival at 6
years.
Primary Secondary Limb Patient
patency %* patency %* salvage %* survival %*
Factor (p value) (p value) (p value) (p value)
Gender
Male 24 60 81 53
Female 26 56 54 37
(0.7) (0.1) (0.006) (0.02)
Diabetes
Present 25 60 59 37
Absent 23 58 80 55
(0.08) (0.2) (0.0005) (0.01)
Hypertension
Present 36 73 75 48
Absent 18 52 73 50
(0.3) (0.2) (0.5) (0.9)
Ischaemic heart disease
Present 30 65 76 50
Absent 20 55 66 38
(0.5) (0.3) (0.4) (0.05)
Aspirin
Yes 25 67 75 59
No 18 51 74 47
(0.3) (0.04) (0.2) (0.03)
Indication
CLI 29 58 44
None CLI 15 70 72
(0.2) (0.01) (0.0002)
Run-off vessels
Z1 17 55 59 36
>1 26 62 84 57
(0.6) (0.2) (0.03) (0.06)
Level of distal anastomoses
Popliteal/tibioperoneal 24 62 84 60
25 58 67 41
(0.2) (0.06) (0.08) (0.08)
Postoperative warfarin
Yes 19 52 65 43
No 26 69 84 53
(0.1) (0.02) (0.6) (0.5)
Graft type
In situ 29 65 82
Reversed 26 63 73
Composite 0 24 35
(0.07) (0.03) (0.1)
Composite vs. others** (0.05) (0.02) (0.02)
Early graft thrombectomy
Yes 8 0
No 62 67
(<0.001) (<0.001)
*Cumulative percentages. **Comparison of outcomes of composite grafts to reversed and in situ grafts. CLI,
critical limb ischaemia. Significant variables with p<0.05 are in bold.
for intermittent claudication.32–35 However, in a pre- intervention program to idntify and treat graft threat-
ening run-off disease which develops due to the pro-vious study from our unit in which the majority of
patients had CLI,30 poor run-off was also found to be gression of underlying atherosclerosis.
None of the co-morbid factors played a significanta significant factor. The lack of influence of run-off
disease on long-term secondary patency in the present role in either primary or secondary graft patency.
This is in keeping with reports from most modernstudy may reflect the ability of the surveillance and
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Table 3. Multivariate analysis of significant factors affecting outcome.
Outcome Factor Odds ratio 95% CI* p value
Secondary patency Thrombectomy 0.2 0.09/0.29 <0.001
Limb salvage Diabetes 0.5 0.26/0.82 0.008
Run-off vessels Z1 vs. >1 0.6 0.42/0.99 0.047
Thrombectomy 0.2 0.12/0.47 <0.001
Patient survival Gender (M/F) 1.7 1.04/2.77 0.020
Use of aspirin 1.8 1.12/2.77 0.001
CLI 0.3 0.15/0.72 0.006
Multivariate analysis performed using the backward stepwise entry method. *95% confidence interval (CI).
series.8,21,24,36 However, in the past there have been other recent reports.21,22,25,27,41,42 We found that long-
many conflicting reports concerning the influence of term survival was better in patients without critical
some of these factors on graft patency.12,13,33,37 The ischaemia, in males, and in those who took aspirin
reason why these factors no longer appear to affect postoperatively. The presence of critical limb ischaemia
graft patency in more recent reports is not clear. Post- tends to be associated with a high mortality rate from
operative surveillance and the ability of currently myocardial infarctions and cerebrovascular events.43,44
available drugs to effectively control diseases such as Thus the reduced survival of patients with critical
hypertension and diabetes are plausible explanations. ischaemia in this study supports these observations.
Limb salvage is an important outcome of any re- Men tended to do better than women in our study.
vascularisation procedure, particularly as it is re- The lower median age of the males in this study may
cognised that a patent graft does not necessarily explain why they survived longer than the females.
guarantee limb preservation. Most authors have stated The effect of gender on survival is, however, con-
that graft surveillance has resulted in improved limb troversial. Thus whilst Harris et al.41 found no gender
salvage rates.5,6,9,38 However, these claims are mostly difference in long-term survival, Magnant et al.14 and
based on retrospective non-randomised studies. The Enzler et al.15 found that mortality was higher in
most often quoted randomised study by Lundell et al. women whereas Kalman and Johnson found that male
did not report the impact of graft surveillance on limb gender was associated with poor long-term survival.42
salvage.4 The meta-analysis of graft surveillance by Patients taking aspirin had a significantly better
Golledge et al. concluded that graft surveillance did chance of survival. This is in keeping with the findings
not improve limb salvage.39 In this study, we found of the anti-platelet trialists.45 Thus aspirin is beneficial
that poor distal run-off, presence of diabetes and grafts in preventing cardiovascular morbidity and mortalitythat required postoperative thrombectomy had sig-
and should be prescribed to patients after re-nificantly worse limb salvage rates. It was somewhat
vascularisation. This is despite the fact that aspirin hassurprising to find that poor run-offs still influenced
not been shown to improve graft patency in ran-amputation rates because we expected that our intense
domised studies.46,47postoperative surveillance and intervention policy for
In conclusion, this study has analysed the clinicalboth graft and native vessels stenosis would have
variables that may influence outcome in a consecutivereduced the effects of poor run-off.
series of vein graft bypass that have undergone graftAlthough the influence of diabetes on limb salvage
surveillance. The only factor that significantly in-has been controversial,3,21,25,30 we found that limb loss
fluenced long-term primary graft patency was the usewas significantly higher in diabetic patients. This find-
of composite vein. This stresses the importance ofing is in keeping with two other recent studies,8,40
designing the operation in such a way that goodsuggesting that diabetes is indeed an important de-
quality long saphenous vein is used if at all possible.terminant of limb salvage. It is perhaps not surprising
The only factor that significantly influenced long-termthat diabetes did not impair secondary patency and
secondary graft patency was early graft thrombectomy.yet did adversely affect limb salvage. This is because
This suggests that efforts to improve secondary pa-it is well recognised that diabetic patients tend to
tency rates should focus on reducing graft failureundergo more amputations in spite of patent grafts.
within the first postoperative month. Limb salvageEarly graft thrombectomy adversely affected graft pa-
rates are worse in diabetic patients and limbs withtency rates in this and other studies27 and thus a lower-
poor run-off vessels. Unfortunately neither of theselimb salvage rate in this group is not unexpected.
Our 6-year patient survival of 45% is in line with variables can be manipulated by the vascular surgeon
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